Validation of ROS1 by immunohistochemistry against fluorescent in situ hybridisation on cytology and small biopsy samples in a large teaching hospital
Wallace, A. J.
Khan, K. A.
Lindsay, Colin R
Blackhall, Fiona H
Rana, D. N.
AffiliationManchester University NHS Foundation Trust. The Christie NHS Foundation Trust.
MetadataShow full item record
AbstractObjective: This is a prospective evaluation of ROS1 analysis by IHC against FISH on cytology and small biopsy samples in a routine diagnostic setting and demonstrates both technical and clinical validation. Methods: From 1st March to 31st December 2019, cytology cell blocks and small biopsy samples from a selected cohort of NSCLC patients were concurrently tested for ROS1 gene rearrangement by Vysis 6q22 Break Apart FISH probe and IHC using Cell Signalling D4D6 antibody. Mismatch cases were tested by an RNA fusion NGS panel. Results: In a prospective population of 95 cases, 91 were negative and 2 were positive by both FISH and IHC. Both dual positive cases were female never smokers and benefited from TKI treatment. Another 2 cases were positive by FISH but negative by IHC and repeat by NGS showed one to be negative but one failed. Turnaround time for IHC was 0 to 8 days from request to authorisation whilst that of FISH was 9 to 42 days at a cost of £51 and £159 respectively. Conclusion: IHC to assess for the protein product of ROS1 gene rearrangement on cytology cell blocks and small biopsy samples in a routine setting is a promising screening method to assess eligibility for TKI treatment with positive and indeterminate cases confirmed by FISH or NGS as it has good NPV, faster turnaround time and is cost effective with proven technical and clinical validation
CitationNarine N, Wallace A, Dore J, O’Leary-Jackson S, Al Najjar H, Bailey S, et al. Validation of ROS1 by immunohistochemistry against fluorescent in situ hybridisation on cytology and small biopsy samples in a large teaching hospital. Cytopathology. 2021 Jun 15.
- Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
- Authors: Wu J, Lin Y, He X, Yang H, He P, Fu X, Li G, Gu X
- Issue date: 2016 Aug 4
- Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
- Authors: Lim SM, Chang H, Cha YJ, Liang S, Tai YC, Li G, Pestova E, Policht F, Perez T, Soo RA, Park WY, Kim HR, Shim HS, Cho BC
- Issue date: 2017 Sep
- On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
- Authors: Mescam-Mancini L, Lantuéjoul S, Moro-Sibilot D, Rouquette I, Souquet PJ, Audigier-Valette C, Sabourin JC, Decroisette C, Sakhri L, Brambilla E, McLeer-Florin A
- Issue date: 2014 Feb
- Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
- Authors: Selinger CI, Li BT, Pavlakis N, Links M, Gill AJ, Lee A, Clarke S, Tran TN, Lum T, Yip PY, Horvath L, Yu B, Kohonen-Corish MR, O'Toole SA, Cooper WA
- Issue date: 2017 Feb
- ROS1 rearrangements in non-small cell lung cancer: screening by immunohistochemistry using proportion of cells staining without intensity and excluding cases with MAPK pathway drivers improves test performance.
- Authors: Prall OWJ, Browning J, Nastevski V, Caporarello S, Bates B, Hewitt CA, Arenas A, Lamb G, Howlett K, Arnolda R, Adeloju R, Stuart S, Xu H, Fellowes A, Fox SB
- Issue date: 2021 Oct 8